AZN 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，不過公司股利評分優異，若想穩定收息，仍可以考慮持續持有。但若僅以價值投資為目標可以減碼換股操作
AZN 近期報酬表現
-0.50%
Astrazeneca plc
1.05%
同產業平均
0.48%
S&P500
與 AZN 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
NVS | Novartis ag | 2 分 | 4 分 | 5 分 | 2 分 | 5 分 | |
SNY | Sanofi s.a. | 3 分 | 3 分 | 4 分 | 2 分 | 5 分 | |
MRK | Merck & co. , inc. | 3 分 | 4 分 | 5 分 | 3 分 | 5 分 | |
GSK | Gsk plc | 3 分 | 5 分 | 4 分 | 2 分 | 5 分 | |
GMAB | Genmab a/s | 5 分 | 3 分 | 3 分 | 1 分 | 1 分 |
- NVS Novartis ag價值 2 分趨勢 4 分波段 5 分籌碼 2 分股利 5 分查看更多
AZN 公司資訊
AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and includes the Alexion Rare Disease portfolio comprising approximately 178 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies. It also offers investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus.